Recent Updates
Recently added Catalysts

RP5063

Phase 2

Acute Schizophrenia | Small molecule | Psychiatry |Reviva Pharmaceuticals Holdings, Inc.|Last Updated: Aug 7, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment234
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01490086RP5063 in Subjects With Schizophrenia or Schizoaffective DisorderPHASE2 COMPLETED 234Dec 1, 2011Mar 1, 2013Aug 7, 2025 -
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
RP5063DRUGdaily
placeboDRUGdaily
aripiprazoleDRUGdaily
Unlock Study Design Details